Harnessing pharmaceutical innovation for anti-cancer drugs: Some findings from the Italian regions
| Autor: | Milena Vainieri, Davide Golinelli, Maria Pia Fantini, Federico Vola, Bruna Vinci |
|---|---|
| Přispěvatelé: | Vola, Federico, Vinci, Bruna, Golinelli, Davide, Fantini, Maria Pia, Vainieri, Milena |
| Rok vydání: | 2019 |
| Předmět: |
Pharmaceuticals governance tools
Antineoplastic Agents Pharmaceuticals governance 03 medical and health sciences 0302 clinical medicine Economic indicator Health care Humans Innovation governance 030212 general & internal medicine Clinical governance Public economics business.industry 030503 health policy & services Health Policy Corporate governance Open data Italy Pharmaceutical Preparations Anti cancer drugs Financial sustainability Business 0305 other medical science Delivery of Health Care Qualitative research |
| Zdroj: | Health policy (Amsterdam, Netherlands). 124(12) |
| ISSN: | 1872-6054 |
| Popis: | Background Governing the provision of innovative drugs is unanimously recognized as a key factor in steering the future of health care systems, by jointly affecting health outcomes and financial sustainability. Aim of the study This paper describes the recent reforms in Italy governing the provision of innovative oncological drugs, with a focus on the different strategies implemented by the regions. It provides some preliminary findings about economic performance potentially associated with different governance models. Methods We conducted a qualitative study based on 26 face-to-face semi-structured interviews with the Regional Directors of the pharmaceutical sector of the 13 regions involved in the study. The interviews were analysed to detect the various tools regions have adopted to manage prescriptions of innovative oncological drugs and different regional models were mapped. Additionally, we collected relevant information on the regional economic outcomes from national open data sources. Results The 13 Italian regions strongly differ in how they apply national instruments and in how they devise regional governance tools. Analysis of the main economic indicators highlights that there is no direct relationship between strategies applied and performance achieved, although some preliminary results suggest a potential association between certain clinical governance models and different appropriateness performances. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect